Evidence map›Paper›PMID 39070960›Full record

ArticleContemporary clinical trials communications2024

Global trends in clinical trials and interventions for the metabolic syndrome: A comprehensive analysis of the WHO International Clinical Trials platform.

Ndivhuwo Muvhulawa, Phiwayinkosi V Dludla, Musawenkosi Ndlovu, Yonela Ntamo, Asanda Mayeye, Nomahlubi Luphondo, Nokulunga Hlengwa, Albertus K Basson, Sihle E Mabhida, Sidney Hanser and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary clinical trials communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ndivhuwo MuvhulawaCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Phiwayinkosi V DludlaCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Musawenkosi NdlovuCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Yonela NtamoCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Asanda MayeyeCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Nomahlubi LuphondoCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.
Nokulunga HlengwaDepartment of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, 3886, South Africa.
Albertus K BassonDepartment of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa, 3886, South Africa.
Sihle E MabhidaNon-Communicable Diseases Research Unit, South African Medical Research Council, Tygerberg, 7505, South Africa.
Sidney HanserDepartment of Physiology and Environmental Health, University of Limpopo, Sovenga, 0727, South Africa.
Sithandiwe E Mazibuko-MbejeDepartment of Biochemistry, North-West University, Mafikeng Campus, Mmabatho, 2735, South Africa.
Bongani B NkambuleSchool of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, 4000, South Africa.
Duduzile NdwandweCochrane South Africa, South African Medical Research Council, Tygerberg, 7505, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome has emerged as a significant global public health concern, necessitating comprehensive examination alongside cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2D). This study provides a comprehensive analysis of clinical trials, drawing upon data sourced from the International Clinical Trials Registry Platform (ICTRP), until April 2023. Information pertaining to trial attributes and intervention features was gathered and subsequently summarized. Among the 2379 studies found on ICTRP from 18 clinical registries, ClinicalTrials.gov was the most popular with 55 % of the studies, based on data emerging from the United States. Most trials were for treatment (44 %) and prevention (17 %), with fewer focused on basic science, and diagnostic purposes. Diet and exercise were the most prominent, with 710 and 247 studies, respectively. Metformin and statins emerge as leading pharmacological therapies, reflecting the prevalence of CVD and T2D in the context of metabolic syndrome. However, there is growing recognition of other promising interventions, such as Glucagon-Like Peptide-1 agonists and Dipeptidyl Peptidase IV inhibitors, which offer potential in slowing the progression of metabolic syndrome-related conditions. Notably, clinical trials primarily assessed diagnostic markers like lipid profiles, insulin, and blood pressure, rather than body mass and body mass index. These parameters are crucial for evaluating the effectiveness and safety of interventions for metabolic syndrome due to its multi-condition nature. Most studies aimed to address general symptom relief, while highlighting a need for additional well-designed treatment trials with rigorous methodologies in accordance with the World Health Organization's guidance for consistent evaluation and treatment.

Indexed as

Demographic characteristicsGlobal trendsInternational Clinical Trials Registry Platform (ICTRP)Metabolic syndromeTreatment modalities

Identifiers

PMID39070960
PMCPMC11283015

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.